What does Accent Microcell do?

Accent Microcell Ltd is a Micro Cap company in the Pharmaceuticals & Biotechnology industry, reporting net sales of 59 Cr and a net profit of 7 Cr for the quarter ending March 2023. It was incorporated in 2012 and became a public company in December 2022, with a market cap of Rs 552 Cr.

Overview:<BR>Accent Microcell Ltd operates in the Pharmaceuticals & Biotechnology industry and is categorized as a Micro Cap company.<BR><BR>History:<BR>The company was originally incorporated in 2012 as "Accent Microcell Private Limited" and later converted to a Public Limited Company, changing its name to "Accent Microcell Limited" on December 23, 2022. The most recent quarterly results reported net sales and net profit for the period ending March 2023.<BR><BR>Financial Snapshot:<BR>- Net Sales: 59 Cr (Quarterly Results - Mar 2023)<BR>- Net Profit: 7 Cr (Quarterly Results - Mar 2023)<BR>- Market Cap: Rs 552 Cr (Micro Cap)<BR><BR>Key Metrics:<BR>- P/E: 17.00<BR>- Industry P/E: 35<BR>- Dividend Yield: 0.38%<BR>- Debt Equity: -0.36<BR>- Return on Equity: 20.18%<BR>- Price to Book: 3.38<BR><BR>Contact Details:<BR>Registrar Address: Not available.

When is the next results date for Accent Microcell?

No Upcoming Board Meetings

Has Accent Microcell declared dividend?

Accent Microcell Ltd has declared a 10% dividend, amounting to 1 per share, with an ex-date of September 2, 2024. Despite this declaration, the company's total returns have been negative over various periods, indicating a decline in price performance.

Accent Microcell Ltd has declared a 10% dividend.<BR><BR>Dividend Details:<BR>- Percentage announced: 10%<BR>- Amount per share: 1 per share<BR>- Ex-date: 02 Sep 24<BR><BR>Dividend Yield: 0.38%.<BR><BR>Total Returns by Period:<BR>In the last 6 months, the price return was -13.53%, the dividend return was 0%, resulting in a total return of -13.53%.<BR><BR>Over the past year, the price return was -14.81%, the dividend return was 0.34%, leading to a total return of -14.47%.<BR><BR>For the 2-year period, there was no price return, no dividend return, and the total return remained at 0.0%.<BR><BR>In the 3-year period, both the price return and dividend return were 0%, resulting in a total return of 0.0%.<BR><BR>For the 4-year period, there were no changes in price or dividends, maintaining a total return of 0.0%.<BR><BR>In the 5-year period, again, there was no price return or dividend return, keeping the total return at 0.0%.<BR><BR>Overall, while Accent Microcell has declared a dividend, the total returns over various periods indicate a decline in price returns, with limited dividend contributions, suggesting a challenging performance landscape for the company.

Who are the peers of the Accent Microcell?

Accent Microcell's peers include NGL Fine Chem, Kilitch Drugs, Sakar Healthcare, Venus Remedies, Ind-Swift Labs., Zim Laboratories, Albert David, Kerala Ayurveda, Shree Ganesh Rem, and Jenburkt Pharma. In terms of management risk, Accent Microcell has an average rating, with growth rated as good and a 1-year return of -6.66%.

Peers: The peers of Accent Microcell are NGL Fine Chem, Kilitch Drugs, Sakar Healthcare, Venus Remedies, Ind-Swift Labs., Zim Laboratories, Albert David, Kerala Ayurveda, Shree Ganesh Rem, and Jenburkt Pharma.<BR><BR>Quality Snapshot: Excellent management risk is observed at NGL Fine Chem, Venus Remedies, Albert David, and Shree Ganesh Rem, while Average management risk is found at Accent Microcell, Sakar Healthcare, Zim Laboratories, and the rest. Below Average management risk is present at Kilitch Drugs, Ind-Swift Labs., and Kerala Ayurveda. Growth is Excellent at Kilitch Drugs, Good at Accent Microcell, Average at Venus Remedies, Sakar Healthcare, and Shree Ganesh Rem, while Below Average growth is seen at NGL Fine Chem, Ind-Swift Labs., Zim Laboratories, Albert David, and Kerala Ayurveda. Capital Structure is Excellent at NGL Fine Chem, Venus Remedies, Accent Microcell, and Shree Ganesh Rem, Good at Kilitch Drugs, Average at Sakar Healthcare and Zim Laboratories, and Below Average at Ind-Swift Labs. and Kerala Ayurveda.<BR><BR>Return Snapshot: The peer with the highest 1-year return is Kilitch Drugs at 37.66%, while the lowest is NGL Fine Chem at -47.10%. Accent Microcell's 1-year return is -6.66%, which is higher than NGL Fine Chem but lower than Kilitch Drugs. Additionally, Ind-Swift Labs., Kerala Ayurveda, and Albert David have negative six-month returns.

Who are the top shareholders of the Accent Microcell?

The top shareholders of Accent Microcell are Nitin Jasvantbhai Patel with 15.59%, Kantilal Pachan Vadia with 9.19%, and individual investors collectively owning 37.49%. There are no pledged promoter holdings, and the company has minimal foreign institutional investment at 0.01%, with no mutual fund holdings.

The top shareholders of Accent Microcell include the promoters, who hold the majority of the shares. The promoter with the highest holding is Nitin Jasvantbhai Patel, with a stake of 15.59%. The highest public shareholder is Kantilal Pachan Vadia, who holds 9.19%. Additionally, individual investors collectively own 37.49% of the company. There are no pledged promoter holdings, and the company is held by one foreign institutional investor (FII) at 0.01%. Mutual funds currently do not hold any shares in Accent Microcell.

How big is Accent Microcell?

As of 24th July, Accent Microcell Ltd has a market capitalization of 650.00 Cr, with recent net sales of 58.81 Cr and a net profit of 7.06 Cr for the quarter ending March 2023.

As of 24th July, <BR><BR>Market Cap: Accent Microcell Ltd has a market capitalization of 650.00 Cr and is classified as a Micro Cap.<BR><BR>Recent Quarterly Performance: For the latest quarter ending March 2023, the company reported Net Sales of 58.81 Cr and a Net Profit of 7.06 Cr.<BR><BR>Balance Sheet Snapshot: The latest annual reporting period is March 2024, with Shareholder's Funds amounting to 163.83 Cr and Total Assets of 204.84 Cr.

How has been the historical performance of Accent Microcell?

Accent Microcell has shown consistent growth over the past four years, with net sales increasing from 165.71 Cr in Mar'22 to 264.58 Cr in Mar'25, and profit after tax rising from 5.89 Cr to 33.06 Cr, reflecting strong financial performance and improved operational efficiency.

Answer:<BR>The historical performance of Accent Microcell shows a consistent growth trend in net sales and profitability over the past four years.<BR><BR>Breakdown:<BR>Accent Microcell's net sales have increased from 165.71 Cr in Mar'22 to 264.58 Cr in Mar'25, reflecting a strong upward trajectory. The total operating income has followed a similar trend, rising from 165.71 Cr in Mar'22 to 264.58 Cr in Mar'25. The company's operating profit (PBDIT) has also seen significant growth, climbing from 14.80 Cr in Mar'22 to 48.32 Cr in Mar'25, with an operating profit margin of 15.84% in Mar'25. Profit before tax has risen from 7.59 Cr in Mar'22 to 43.76 Cr in Mar'25, while profit after tax has increased from 5.89 Cr to 33.06 Cr in the same period, resulting in a PAT margin of 12.5% in Mar'25. The company's total assets have grown from 94.61 Cr in Mar'22 to 228.37 Cr in Mar'25, with total liabilities increasing from 94.61 Cr to 228.37 Cr as well. Cash flow from operating activities has improved significantly, reaching 24.00 Cr in Mar'25, while the net cash inflow has also increased to 2.00 Cr. Overall, Accent Microcell has demonstrated robust financial growth and improved operational efficiency over the years.

Is Accent Microcell technically bullish or bearish?

As of October 16, 2025, Accent Microcell shows a mildly bullish trend supported by daily moving averages and Bollinger Bands, despite some caution from bearish signals in the weekly MACD and KST.

As of 16 October 2025, the technical trend for Accent Microcell has changed from sideways to mildly bullish. The daily moving averages indicate a mildly bullish stance, while the weekly Dow Theory also supports this with a mildly bullish signal. However, the weekly MACD and KST are mildly bearish, which introduces some caution. The Bollinger Bands are bullish on both weekly and monthly time frames, suggesting potential upward momentum. Overall, the current technical stance is mildly bullish, driven primarily by the daily moving averages and Bollinger Bands, despite some bearish signals from the MACD and KST.

Is Accent Microcell overvalued or undervalued?

As of November 28, 2025, Accent Microcell is considered fairly valued with a PE ratio of 23.75, an EV to EBITDA of 17.72, and a ROCE of 18.20%, outperforming the Sensex with a year-to-date return of 21.22%.

As of 28 November 2025, the valuation grade for Accent Microcell has moved from very attractive to attractive. The company is currently considered fairly valued. Key ratios include a PE ratio of 23.75, an EV to EBITDA of 17.72, and a ROCE of 18.20%. <BR><BR>In comparison to its peers, Accent Microcell's PE ratio is lower than Sun Pharma's 38.03 and Divi's Lab's 69.12, which are categorized as expensive. However, it is slightly higher than Cipla's 22.71 and Dr. Reddy's Labs' 18.19, both of which are rated attractive. Notably, Accent Microcell has outperformed the Sensex with a year-to-date return of 21.22% compared to the Sensex's 10.82%, reinforcing its valuation story.

Which are the latest news on Accent Microcell?

Why is Accent Microcell falling/rising?

As of 04-Dec, Accent Microcell Ltd's stock price is at 341.35, down 0.36%. Despite this decline, the stock has shown strong performance with a 26.43% year-to-date increase, although recent trading activity has decreased significantly.

As of 04-Dec, Accent Microcell Ltd's stock price is currently at 341.35, reflecting a decrease of 1.25, or 0.36%. Despite this decline, the stock has shown strong performance over various periods, with a 6.72% increase over the past week and an impressive 18.90% rise over the past month. Year-to-date, the stock has grown by 26.43%, significantly outperforming the Sensex, which has only increased by 10.10% in the same timeframe.<BR><BR>Today's performance indicates that the stock is underperforming its sector by 0.65%. Additionally, while it is trading above its moving averages across multiple time frames, there has been a notable decline in investor participation, with delivery volume dropping by 30.69% compared to the 5-day average. This decrease in trading activity could be contributing to the current price drop.<BR><BR>Moreover, the stock is just 2.83% away from its 52-week high of Rs 351, suggesting that it has been performing well overall, but the recent dip could be attributed to reduced trading volumes and sector underperformance.